Obstructive Lung Diseases |

Direct Costs of Acute Exacerbation of COPD Patients in a Second Level Hospital FREE TO VIEW

Hakan Tanriverdi*, MD; Halit Besir, MD; Gulseren Pekbak, MD
Author and Funding Information

State Hospital Chest Diseases Clinic, Erzincan, Turkey

Chest. 2012;142(4_MeetingAbstracts):659A. doi:10.1378/chest.1389197
Text Size: A A A
Published online



PRESENTED ON: Wednesday, October 24, 2012 at 01:30 PM - 02:30 PM

PURPOSE: We aimed to determine the costs of acute exacerbation of COPD in one year period in a second level hospital. and drawing attention to this big health problem and its economic burden.

METHODS: Hospital automation system rewieved between january 01 - december 31 in year of 2011. Patients who had diagnosed COPD or acute exacerbation of COPD were included study. Paitents total costs, medicine cost, bed cost and proportion of these recorded. Age, gender and lenght of hospital stay were recorded. 1 turkish liras equals 0,55 US $.

RESULTS: 381 patients enrolled study. mean stay of hospitaliization 9,0±4,3 days. mean total cost of acute exacerbation of COPD was found 1100±618 turkish liras.($614±345). medicine, antibiotic and bed costs were 35%, 14% and 25,9% of total cost, respectively. we didn't found significant corelaiton between gender, severity of COPD and chronic respiratory failure. but we found significant corelation between age and costs.(Pearson corelation 0,144, p=0,001).

CONCLUSIONS: COPD is an important health problem in developed countries. Also it is a big problem in developing countries like Turkey. COPD is a frequent cause of hospitalizations, disability, and death, and generates a great social and economic burden. most of direct cost of COPD is due to hospitalization. antibiotic use, and bed cost are the biggest part of costs. So we should prevent development of COPD by avoiding risk factors like smoking and preventing exacerbations.

CLINICAL IMPLICATIONS: COPD is an important health problem in worldwide. we should prevent and treat COPD to decrease the economic burden.

DISCLOSURE: The following authors have nothing to disclose: Hakan Tanriverdi, Halit Besir, Gulseren Pekbak

No Product/Research Disclosure Information

State Hospital Chest Diseases Clinic, Erzincan, Turkey




Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Find Similar Articles
CHEST Journal Articles
PubMed Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543